期刊
AGING CELL
卷 19, 期 3, 页码 -出版社
WILEY
DOI: 10.1111/acel.13109
关键词
Alzheimer's disease (AD); amyloid-beta (A beta); brain; cell cycle; chromosome instability (CIN); cohesinopathy; cyclin-dependent kinase (CDK) inhibitor; mitosis; mouse; Shugoshin 1 (Sgo1)
资金
- NCI NIH HHS [NCI R01CA094962, NCI R01CA213987] Funding Source: Medline
The cell cycle and its regulators are validated targets for cancer drugs. Reagents that target cells in a specific cell cycle phase (e.g., antimitotics or DNA synthesis inhibitors/replication stress inducers) have demonstrated success as broad-spectrum anticancer drugs. Cyclin-dependent kinases (CDKs) are drivers of cell cycle transitions. A CDK inhibitor, flavopiridol/alvocidib, is an FDA-approved drug for acute myeloid leukemia. Alzheimer's disease (AD) is another serious issue in contemporary medicine. The cause of AD remains elusive, although a critical role of latent amyloid-beta accumulation has emerged. Existing AD drug research and development targets include amyloid, amyloid metabolism/catabolism, tau, inflammation, cholesterol, the cholinergic system, and other neurotransmitters. However, none have been validated as therapeutically effective targets. Recent reports from AD-omics and preclinical animal models provided data supporting the long-standing notion that cell cycle progression and/or mitosis may be a valid target for AD prevention and/or therapy. This review will summarize the recent developments in AD research: (a) Mitotic re-entry, leading to the amyloid-beta accumulation cycle, may be a prerequisite for amyloid-beta accumulation and AD pathology development; (b) AD-associated pathogens can cause cell cycle errors; (c) thirteen among 37 human AD genetic risk genes may be functionally involved in the cell cycle and/or mitosis; and (d) preclinical AD mouse models treated with CDK inhibitor showed improvements in cognitive/behavioral symptoms. If the amyloid-beta accumulation cycle is an AD drug target concept is proven, repurposing of cancer drugs may emerge as a new, fast-track approach for AD management in the clinic setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据